Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,857 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Droplet formation in a microchannel network.
Nisisako T, Torii T, Higuchi T. Nisisako T, et al. Among authors: higuchi t. Lab Chip. 2002 Feb;2(1):24-6. doi: 10.1039/b108740c. Epub 2002 Jan 18. Lab Chip. 2002. PMID: 15100856
Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy.
Nagahashi M, Ishikawa E, Nagai T, Kanaoka H, Oshiro A, Togashi Y, Hattori A, Tsuchida J, Higuchi T, Nishimukai A, Murase K, Takatsuka Y, Kihara T, Ling Y, Okuda S, Hirota S, Miyoshi Y. Nagahashi M, et al. Among authors: higuchi t. Breast Cancer. 2025 Jan 14. doi: 10.1007/s12282-025-01665-y. Online ahead of print. Breast Cancer. 2025. PMID: 39808396
The most important prognostic factors for predicting major adverse cardiovascular, cerebrovascular, and renal events during 5-year follow-up of patients with chronic kidney disease with or without haemodialysis.
Toyama T, Kasama S, Sato M, Sano H, Ueda T, Sasaki T, Nakahara T, Higuchi T, Tsushima Y, Kurabayashi M. Toyama T, et al. Among authors: higuchi t. Nucl Med Commun. 2025 Jan 10. doi: 10.1097/MNM.0000000000001943. Online ahead of print. Nucl Med Commun. 2025. PMID: 39791390
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N. Yamashita T, et al. Among authors: higuchi t. J Clin Oncol. 2025 Jan 9:JCO2401888. doi: 10.1200/JCO-24-01888. Online ahead of print. J Clin Oncol. 2025. PMID: 39787453
2,857 results